College of Pharmaceutical Sciences, Key Laboratory of Pharmaceutical Quality Control of Hebei Province, Institute of Life Science and Green Development, Hebei University, Baoding 071002, China.
Department of Urology, Peking University International Hospital, Beijing 102206, China.
Biomed Pharmacother. 2021 Nov;143:112232. doi: 10.1016/j.biopha.2021.112232. Epub 2021 Sep 25.
Aptamers are single stranded oligonucleotides with specific recognition and binding ability to target molecules, which can be obtained by Systematic Evolution of Ligands by Exponential Enrichment (SELEX). Aptamers have the advantages of low molecular weight, low immunogenicity, easy modification and high stability. They play promising role in promoting food safety, monitoring the environment and basic research, especially in clinical diagnosis and therapeutic drugs. To date, great achievements regarding the selection, modifications and application of aptamers have been made. However, since it is still a challenge to obtain aptamers with high affinity in a more effective way, few aptamer-based products have already successfully entered into clinical use. This review aims to provide a thorough overview of the latest advances in this rapidly developing field, focusing on aptamer screening methods for different targets, the structure of the interaction between aptamers and target substances, and the challenges and potential of current therapeutic aptamers.
适体是具有特定识别和结合靶分子能力的单链寡核苷酸,可以通过指数富集的配体系统进化(SELEX)获得。适体具有分子量低、免疫原性低、易于修饰和稳定性高等优点。它们在促进食品安全、监测环境和基础研究方面发挥着重要作用,特别是在临床诊断和治疗药物方面。迄今为止,在适体的筛选、修饰和应用方面已经取得了巨大的成就。然而,由于以更有效的方式获得高亲和力的适体仍然是一个挑战,因此很少有基于适体的产品已经成功进入临床应用。本综述旨在全面概述这一快速发展领域的最新进展,重点介绍针对不同靶标的适体筛选方法、适体与靶物质相互作用的结构,以及当前治疗性适体的挑战和潜力。